Following a limited submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2021. Refer to TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. |
|
Medicine details |
|
| Medicine name | belimumab (Benlysta®) |
| Formulation | 120 mg powder for concentrate for solution for infusion, 400 mg powder for concentrate for solution for infusion |
| Reference number | 3778 |
| Indication | Treatment of systemic lupus erythematosus in children |
| Company | GlaxoSmithKline |
| BNF chapter | Immunological products & vaccines |
| Assessment type | Limited |
| Status | Superseded |
| Advice number | 0720 |
| NMG meeting date | 25/06/2020 |
| AWMSG meeting date | 15/07/2020 |
| Date of issue | 04/08/2020 |
| NICE guidance | TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Commercial arrangement | PAS |